Molecular Partners AG (MOLN)
3.87
+0.16
(+4.31%)
USD |
NASDAQ |
May 16, 16:00
Molecular Partners Cash from Investing (Quarterly): 21.20M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 21.20M |
| September 30, 2023 | 20.27M |
| June 30, 2023 | 4.600M |
| March 31, 2023 | 3.639M |
| December 31, 2022 | 35.85M |
| September 30, 2022 | -28.30M |
| Date | Value |
|---|---|
| June 30, 2022 | -12.28M |
| March 31, 2022 | -101.29M |
| December 31, 2021 | 10.78M |
| September 30, 2021 | -26.12M |
| June 30, 2021 | -9.448M |
| March 31, 2021 | 0.4555M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-101.29M
Minimum
Mar 2022
35.85M
Maximum
Dec 2022
-6.721M
Average
2.047M
Median
Cash from Investing (Quarterly) Benchmarks
| AC Immune SA | -26.96M |
| CRISPR Therapeutics AG | -97.80M |
| Addex Therapeutics Ltd | -0.0012M |
| NLS Pharmaceutics Ltd | -- |
| MoonLake Immunotherapeutics | -28.80M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -17.00M |
| Cash from Financing (Quarterly) | -0.3157M |
| Free Cash Flow | -66.61M |
| Free Cash Flow Per Share (Quarterly) | -0.5277 |
| Free Cash Flow to Equity (Quarterly) | -17.34M |
| Free Cash Flow to Firm (Quarterly) | -17.34M |
| Free Cash Flow Yield | -53.78% |